| Product Code: ETC8837423 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The market for certolizumab pegol, a biologic treatment for autoimmune diseases like rheumatoid arthritis and Crohns disease, is developing in the Philippines as access to advanced biologics improves. Healthcare providers are increasingly adopting this treatment for its efficacy in managing chronic inflammatory conditions.
The certolizumab pegol market in the Philippines is growing as this biologic drug, used in the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, and psoriatic arthritis, becomes more widely available. Increased awareness of autoimmune diseases and the effectiveness of biologic therapies are key factors contributing to the market`s expansion.
The market for Certolizumab Pegol in the Philippines encounters barriers such as limited awareness among healthcare professionals about newer biologic treatments. There is also the issue of affordability, as the high cost of biologics may restrict access to this treatment option for patients. Additionally, the logistics of distributing such specialized medication across the country, especially to rural areas, presents a significant challenge, leading to inconsistent availability.
The certolizumab pegol market in the Philippines is positioned for growth, especially with the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn`s disease, and psoriasis. Certolizumab pegol, a biologic drug used for the treatment of these conditions, presents a valuable investment opportunity as the demand for effective treatments continues to rise. Investors can explore opportunities in the distribution and marketing of certolizumab pegol, particularly by working with healthcare providers and focusing on patient education to increase awareness of its benefits.
The Philippines government regulates the availability of Certolizumab Pegol, an essential drug used in treating autoimmune conditions. Through the Department of Health (DOH) and the Food and Drug Administration (FDA), policies are in place to ensure that this drug is available to patients who need it. Public health initiatives are also focused on increasing awareness of autoimmune diseases and expanding access to necessary medications, ensuring that Certolizumab Pegol is included in the national formulary.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Certolizumab Pegol Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Certolizumab Pegol Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Certolizumab Pegol Market - Industry Life Cycle |
3.4 Philippines Certolizumab Pegol Market - Porter's Five Forces |
3.5 Philippines Certolizumab Pegol Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Philippines Certolizumab Pegol Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Philippines Certolizumab Pegol Market Revenues & Volume Share, By Dosage Form, 2021 & 2031F |
3.8 Philippines Certolizumab Pegol Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Philippines Certolizumab Pegol Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 Philippines Certolizumab Pegol Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Certolizumab Pegol Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases in the Philippines |
4.2.2 Growing awareness and acceptance of biologic therapies |
4.2.3 Favorable regulatory environment for certolizumab pegol in the country |
4.3 Market Restraints |
4.3.1 High cost of certolizumab pegol treatment limiting patient affordability |
4.3.2 Limited healthcare infrastructure and access to specialized care |
4.3.3 Competition from other biologic therapies in the market |
5 Philippines Certolizumab Pegol Market Trends |
6 Philippines Certolizumab Pegol Market, By Types |
6.1 Philippines Certolizumab Pegol Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Certolizumab Pegol Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Philippines Certolizumab Pegol Market Revenues & Volume, By Single-dose Vial, 2021- 2031F |
6.1.4 Philippines Certolizumab Pegol Market Revenues & Volume, By Single-dose Prefilled Syringe, 2021- 2031F |
6.2 Philippines Certolizumab Pegol Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Philippines Certolizumab Pegol Market Revenues & Volume, By Crohns disease, 2021- 2031F |
6.2.3 Philippines Certolizumab Pegol Market Revenues & Volume, By Active Psoriatic Arthritis, 2021- 2031F |
6.2.4 Philippines Certolizumab Pegol Market Revenues & Volume, By Rheumatoid Arthritis, 2021- 2031F |
6.2.5 Philippines Certolizumab Pegol Market Revenues & Volume, By Ankylosing Spondylitis, 2021- 2031F |
6.2.6 Philippines Certolizumab Pegol Market Revenues & Volume, By Plaque Psoriasis, 2021- 2031F |
6.2.7 Philippines Certolizumab Pegol Market Revenues & Volume, By Axial Spondyloarthritis, 2021- 2031F |
6.3 Philippines Certolizumab Pegol Market, By Dosage Form |
6.3.1 Overview and Analysis |
6.3.2 Philippines Certolizumab Pegol Market Revenues & Volume, By Solution, 2021- 2031F |
6.3.3 Philippines Certolizumab Pegol Market Revenues & Volume, By Injection, 2021- 2031F |
6.3.4 Philippines Certolizumab Pegol Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Philippines Certolizumab Pegol Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Philippines Certolizumab Pegol Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.4.3 Philippines Certolizumab Pegol Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Philippines Certolizumab Pegol Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 Philippines Certolizumab Pegol Market Revenues & Volume, By Clinic, 2021- 2031F |
6.5.3 Philippines Certolizumab Pegol Market Revenues & Volume, By Hospital, 2021- 2031F |
6.5.4 Philippines Certolizumab Pegol Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Philippines Certolizumab Pegol Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Philippines Certolizumab Pegol Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Philippines Certolizumab Pegol Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 Philippines Certolizumab Pegol Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
7 Philippines Certolizumab Pegol Market Import-Export Trade Statistics |
7.1 Philippines Certolizumab Pegol Market Export to Major Countries |
7.2 Philippines Certolizumab Pegol Market Imports from Major Countries |
8 Philippines Certolizumab Pegol Market Key Performance Indicators |
8.1 Patient adherence rate to certolizumab pegol treatment |
8.2 Number of healthcare facilities offering certolizumab pegol therapy |
8.3 Rate of adverse events reported for certolizumab pegol treatment |
8.4 Physician prescription patterns for certolizumab pegol compared to other biologic therapies |
9 Philippines Certolizumab Pegol Market - Opportunity Assessment |
9.1 Philippines Certolizumab Pegol Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Philippines Certolizumab Pegol Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Philippines Certolizumab Pegol Market Opportunity Assessment, By Dosage Form, 2021 & 2031F |
9.4 Philippines Certolizumab Pegol Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Philippines Certolizumab Pegol Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 Philippines Certolizumab Pegol Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Certolizumab Pegol Market - Competitive Landscape |
10.1 Philippines Certolizumab Pegol Market Revenue Share, By Companies, 2024 |
10.2 Philippines Certolizumab Pegol Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |